BrioHealth Technologies
同心医疗
BrioHealth Technologies is the European subsidiary of Suzhou Concentric Medical (同心医疗), established to commercialize the company's fully magnetically levitated artificial heart technology outside China. Its flagship product is BrioVAD, a next-generation fully magnetically levitated implantable left ventricular assist system designed for patients with heart failure .
The company is currently advancing the BRIOLIFE European clinical trial, which received regulatory approvals in the Netherlands, Austria, and Germany by June 2025, with the first European implant completed at Utrecht University Medical Center that same month . This followed a major strategic funding round in 2025—exceeding $100 million—co-led by Beijing Mentougou Zhuxin Fund, Gaorong Ventures, and Gaoke Xinjun, with continued support from existing backer Sequoia China .
Gaorong Ventures, which co-led that round, described Concentric Medical's U.S. launch of Medicare-covered large-scale clinical trials in 2025 as a milestone for Chinese innovative medical devices going global, noting that BrioHealth's technology had achieved commercialization in China before expanding abroad .
AI-generated — may contain errors, please verify.
Coverage
Rongbao | True Health Medical Lists in Hong Kong, Major Funding Rounds for Embodied AI and Optical Interconnect Companies
From technological innovation to scaled application.
Congratulations to Zhenjiankang Medical on its successful Hong Kong IPO, the "First Listed Company for Puncture Surgical Robots" | Gaorong Ventures News
The Evolution of Innovation in Domestic Medical Devices
Rong Report | HT Aero, Xiwang, Helixon and Others Close Major Funding Rounds; Moonshot AI and Momenta Release Leading Models
Major Funding + Leading Model + Mass Production
Rongbao | Biren Technology and Seyond list successfully in Hong Kong, Moonshot AI completes major funding round
A new chapter begins.
Rongbao | Multiple autonomous driving, nuclear fusion, gaming, and innovative drug companies raise hundreds of millions of RMB in funding
From commercial deployment to world-first breakthroughs, innovation never stands still.
Concentric Medical Raises Over $100 Million in Strategic Funding to Take China's Full Maglev Artificial Heart Global
Gaorong Ventures co-led the round.
Hongshan Healthcare Investing: 17 Years From the Sidelines to Center Stage
Going earlier and deeper has become a defining feature of Hongshan's healthcare investments.
